Edition:
India

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

19.49USD
11:44pm IST
Change (% chg)

$0.41 (+2.18%)
Prev Close
$19.07
Open
$19.40
Day's High
$19.78
Day's Low
$19.21
Volume
277,562
Avg. Vol
546,138
52-wk High
$23.88
52-wk Low
$10.89

Latest Key Developments (Source: Significant Developments)

Coherus Biosciences Reports Second Quarter 2020 Financial Results
Friday, 7 Aug 2020 

Aug 6 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.81.Q2 EARNINGS PER SHARE $0.70.Q2 EARNINGS PER SHARE ESTIMATE $0.33 -- REFINITIV IBES DATA.NET PRODUCT REVENUE FOR Q2 OF 2020 WAS $135.7 MILLION.  Full Article

Coherus Biosciences Prices $200 Million Convertible Senior Subordinated Notes Offering
Wednesday, 15 Apr 2020 

April 15 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES PRICES $200.0 MILLION CONVERTIBLE SENIOR SUBORDINATED NOTES OFFERING.COHERUS BIOSCIENCES- PRICING OF OFFERING OF $200 MILLION AGGREGATE PRINCIPAL AMOUNT OF 1.500% CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2026.  Full Article

Coherus Biosciences proposes offering $200 mln convertible notes
Tuesday, 14 Apr 2020 

April 14 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES ANNOUNCES PROPOSED CONVERTIBLE SENIOR SUBORDINATED NOTES OFFERING.COHERUS BIOSCIENCES ANNOUNCES PROPOSED CONVERTIBLE SENIOR SUBORDINATED NOTES OFFERING.COHERUS SAYS IT PLANS TO SELL $200 MILLION CONVERTIBLE SENIOR SUBORDINATED NOTES MATURING IN 2026.COHERUS -- INTENDS TO USE SOME OF NET PROCEEDS TO FUND COST OF ENTERING INTO CAPPED CALL TRANSACTIONS.  Full Article

Coherus Biosciences Expects Preliminary Unaudited Q1 2020 Net Product Revenue To Be Between $115.0 Mln And $117.5 Mln
Monday, 13 Apr 2020 

April 13 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES INC - EXPECTS PRELIMINARY UNAUDITED Q1 2020 NET PRODUCT REVENUE TO BE BETWEEN $115.0 MILLION AND $117.5 MILLION.COHERUS BIOSCIENCES INC - PRELIM UNAUDITED Q1 2020 NET INCOME IS EXPECTED TO BE BETWEEN $33.5 MILLION AND $38.0 MILLION.COHERUS BIOSCIENCES INC - UDENYCA SAW A 7% UNIT GROWTH IN LAST FOUR WEEKS ENDING MARCH 27, 2020 OVER PREVIOUS FOUR WEEKS.  Full Article

Coherus Biosciences Reports Q4 Earnings Per Share $0.53
Friday, 28 Feb 2020 

Feb 27 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.53.Q4 EARNINGS PER SHARE ESTIMATE $0.72 -- REFINITIV IBES DATA.  Full Article

Coherus Acquires Commercial Rights For Avastin Biosimilar In The United States
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Coherus BioSciences Inc ::COHERUS ACQUIRES COMMERCIAL RIGHTS FOR AVASTIN® BIOSIMILAR IN THE UNITED STATES.COHERUS BIOSCIENCES INC - ACCORDING TO TERMS OF AGREEMENT WITH INNOVENT, COHERUS WILL PAY UP TO $45 MILLION IN MILESTONES.COHERUS BIOSCIENCES INC - FINANCIAL TERMS FOR INNOVENT'S RITUXAN BIOSIMILAR WILL BE SAME WHEN OPTIONED..COHERUS BIOSCIENCES - TO COMMERCIALIZE INNOVENT'S BIOSIMILAR CANDIDATE TO AVASTIN IN UNITED STATES, CANADA.COHERUS BIOSCIENCES INC - TO FILE AVASTIN BLA WITH FDA IN LATE 2020 OR EARLY 2021.  Full Article

KKR Biosimilar Reports 5.6% Stake In Coherus Biosciences As Of Nov. 29
Monday, 2 Dec 2019 

Dec 2 (Reuters) - Coherus BioSciences Inc ::KKR BIOSIMILAR L.P REPORTS 5.6% STAKE IN COHERUS BIOSCIENCES INC AS OF NOV 29, 2019 - SEC FILING.KKR BIOSIMILAR L.P - HAD PREVIOUSLY REPORTED 9.9% STAKE IN COHERUS BIOSCIENCES INC AS OF FEB 29, 2016.KKR BIOSIMILAR L.P-ON NOV 29, ENTERED INTO 10B5-1 SALES PLAN PURSUANT TO WHICH IT MAY SELL UP TO 1 MILLION SHARES OF COHERUS BIOSCIENCES'S COMMON STOCK.  Full Article

Coherus BioSciences Reports Q3 Earnings Per Share Of $0.63
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Coherus BioSciences Inc ::COHERUS BIOSCIENCES REPORTS CORPORATE HIGHLIGHTS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.63.Q3 EARNINGS PER SHARE ESTIMATE $0.51 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS IN MARKETABLE SECURITIES FOR Q3 TOTALED $170.5 MILLION AT SEPTEMBER 30, 2019.NET PRODUCT REVENUE FOR Q3 OF 2019 WAS $111.7 MILLION.Q3 REVENUE VIEW $101.6 MILLION -- REFINITIV IBES DATA.  Full Article

Coherus BioSciences Acquires Commercial Rights For Leading Lucentis Biosimilar In The United States
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Coherus BioSciences Inc ::COHERUS ACQUIRES COMMERCIAL RIGHTS FOR LEADING LUCENTIS BIOSIMILAR IN THE UNITED STATES.COHERUS ACQUIRES COMMERCIAL RIGHTS FOR LEADING LUCENTIS BIOSIMILAR IN THE UNITED STATES.COHERUS BIOSCIENCES INC - WILL MAKE A MID-SINGLE DIGIT MILLION-DOLLAR UPFRONT PAYMENT.COHERUS BIOSCIENCES INC - COMPANIES WILL SHARE PROFITS APPROXIMATELY EQUALLY.COHERUS BIOSCIENCES INC - ACQUIRED EXCLUSIVE RIGHTS FROM BIOEQ IP AG TO COMMERCIALIZE BIOEQ'S BIOSIMILAR CANDIDATE TO LUCENTIS IN U.S..  Full Article

Amgen loses appeal against Coherus BioSciences over patent for purifying proteins
Monday, 29 Jul 2019 

July 29 (Reuters) - u.s. Appeals court upholds dismissal of amgen patent infringement lawsuit against coherus biosciences -- court ruling:.  Full Article

BRIEF-Essent Group Set To Join S&P Midcap 400

* S&P DOW JONES INDICES - ESSENT GROUP SET TO JOIN S&P MIDCAP 400; COHERUS BIOSCIENCES, PATTERSON-UTI ENERGY TO JOIN S&P SMALLCAP 600